Why the study?
Knowledge regarding specific risks in pregnant women based on antithrombin deficiency subtypes is limited, prompting investigation into whether genotyping could aid risk determination and individualize treatment.
Does LMWH thromboprophylaxis and peripartum AT concentrate reduce obstetric complications and VTE in pregnant women with antithrombin deficiency?
Does LMWH thromboprophylaxis and peripartum AT concentrate reduce obstetric complications and VTE in pregnant women with antithrombin deficiency?
Thromboprophylaxis with LMWH and AT concentrate significantly reduced the incidence of preeclampsia and intrauterine fetal death in pregnant women with antithrombin deficiency, suggesting that even 'low-risk' genotypes may benefit from treatment.
Genotyping may refine obstetric risk stratification in AT deficiency; leaves open whether it should guide management.
Background: Hereditary antithrombin (AT) deficiency is a risk factor for venous thromboembolism (VTE) and for obstetric complications and warrants thromboprophylaxis in certain situations. AT deficiency is divided into subtypes with different risk profiles. There is limited knowledge on the specific risks in pregnant women depending on the subtypes. Objectives: The study aim was to investigate whether genotyping pregnant women with AT deficiency could aid in determining complication risk and subsequently help to individualize antepartum and postpartum treatment. Methods: This retrospective cohort study included 43 women with AT deficiency with 106 (61 treated, 40 untreated, and 5 unknown) pregnancies between 1990 and 2022 managed at Karolinska University Hospital. Data were gathered on maternal characteristics, heredity and a history of VTE, thrombophilias, treatment during pregnancy, and maternal and neonatal outcome. Results: = .014). We did not find a statistically significant difference in incidence of VTE or other pregnancy complications between the high-risk and low-risk groups. Conclusion: Our results suggest that untreated women with type IIHBS have a high risk of pregnancy complications, which might warrant thromboprophylaxis regardless of VTE risk.
No takes yet. Share an insight, caveat, or question.
Diemer et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: